CLYM
Climb BioDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
+
Peers tracked
11
U.S. public peers
Grade Position
Below peers
vs peer average
CLYM vs peer average
31/100
CLYM vs. peer average (D vs. C)
Grade spread
A 1 · B 3 · C 4 · D 3
Graded peers loaded
Coverage
11 graded
100% of tracked
Peer overview
ZBIO is the first available peer comparator.
Zenas BioPharma is the closest disclosed budoprutug comparator because Climb's 10-K identifies obexelimab among CD19 bifunctional monoclonal antibody programs in immune-mediated disease, but the usable peer set is still narrow and early-stage rather than robust [#10-K-2026-03-05].
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
CLYM
Climb Bio
ZBIO
Zenas BioPharma
Grade
D
B
Momentum
95
95
Value
41
46
Sentiment
16
44
Setup Bias
Net —
-
Market Cap
-
-
Posture
Defensive
Constructive
Grade position vs ZBIO
CLYM / ZBIO
Grade Position
Below peers
CLYM vs. peer average (D vs. C)
31/100
Momentum
95
CLYMValue
41
ZBIOSentiment
16
ZBIORotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs CLYM
ZBIO is the first peer returned for this comparison set.